Fig. 6From: Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implicationsAbsorbed dose per administrated activity in PCa lesions (for each site of disease), red marrow, pancreas, kidneys and liverBack to article page